Skip to main content

Global Epidemiology of Ebola Disease: A Review of the West African Outbreak | Chapter 1 | Current Trends in Disease and Health Vol. 3


EVD is a disease of humans and other non-human primates caused by Ebola viruses, which was first discovered in 1976. Between 1976 and 2013 there had been 24 outbreaks of the disease. The recent outbreak is the 26th and has seen more deaths than all other outbreaks from the disease combined. This outbreak in West Africa occurred in five countries: Guinea, Liberia, Nigeria, Senegal, and Sierra Leone. In the present research article, the authors reviewed various studies and current research on EVD. EVD was initially restricted to West Africa when the outbreak was first identified but later was reported in several countries around the world, including the USA. Researchers have begun to use mathematical analysis from previous outbreaks to construct the Atangana's Beta Ebola System of Equations (ABESE), which is being used to predict the spread of future outbreaks. The pathophysiology and transmission factors, including the basic and effective reproduction numbers, R0 and Re are discussed in detail. Prevention and control measures, such as proper hygiene techniques (both preventative and post-exposure), education (including educating communities on proper burial techniques), reduction in the consumption and exposure to bush meat, and controlled prevention of the spread of the disease (proper personal protective equipment and protocol upon exposure or in high-risk environments), are outlined. The history and current outbreak are reviewed in detail, which compares the differences in previous outbreaks compared to the current. Earlier (and less deadly) outbreaks have also been traced to the ZEBOV strain, and researchers suggest that the evolutionary rate of gene mutations was accelerated in this current outbreak. Death occurs in approximately 40% of affected individuals within 7-12 days after the onset of initial symptoms and is most often associated with multi-organ failure. Researchers outline the WHO’s criteria for screening and diagnosis, including primary, secondary and entry screening.  There is currently no approved cure for EDV, only supportive and experimental treatment and a currently FDA approved vaccine from Merck & Co’s. There are ongoing trials on the following vaccinations: ZMapp, TKM-Ebola, Favipiravir, cAd3, rVSVΔG-ZEBOVGP12, REGN-EB3 and mAb-114. This review article will attempt to summarize the current state of understanding on EVD and explore the most recent and accepted information including the epidemiology of the disease, etiology and pathophysiology, transmission, prevention and control, history, recent outbreaks in West Africa, clinical manifestations, screening and diagnosis, and treatment and clinical trials.

Author(s) Details

Adekunle O. Sanyaolu
AMOOF Healthcare Consulting, Canada.

Chuku Okorie
Essex County College, Newark, New Jersey, USA.

Olanrewaju Badaru
Epidemiology Division, Nigeria Center for Disease Control (NCDC), Federal Ministry of Health, Nigeria.

Aleksandra Marinkovic
Saint James School of Medicine, BWI, Anguilla.


Comments

Popular posts from this blog

A Prospective Study about Safety and Efficacy of Perioperative Lidocaine Infusion | Chapter 09 | New Horizons in Medicine and Medical Research Vol. 8

 Opioids cause clinically significant side effects such as respiratory depression, immunosuppression, muscle rigidity, negative inotropism, nausea, vomiting, hyperalgesia, urine retention, postoperative ileus, and drowsiness. Perioperative opioids are a major contributor to the United States' and other countries' opioid epidemics. Non-opioid analgesics, particularly lidocaine, are becoming more common for perioperative use as a result of this. A total of 185 adult patients were randomly assigned to one of two groups: control group I (105 patients) [fentanyl group] or group ii (80 patients) [opioid-free anaesthesia group]. Lidocaine 1.5 mg/kg bolus followed by 1.5 mg/kg/h infusion intraoperatively, and 1.5-2 mg/kg/h infusion for 2-8 hours postoperatively were given to patients in both groups at anaesthetic induction. Intraoperatively, both groups received analgesic adjuvants such as diclofenac 75 mg, paracetamol 1 gm, and mgso4 30-50 mg/kg. If the mean arterial pressure (map)

A Brief Study of Middleware Technologies: Programming Applications and Management Systems | Chapter 15 | Novel Research Aspects in Mathematical and Computer Science Vol. 1

  Many platforms, services, applications, hardware, and operating systems are connected through the middleware layer. Because the middleware layer abstracts much low-level complexity and makes applications and software systems portable, it allows disparate systems to interface and function together in harmony. Middleware technologies enable software engineers to swiftly construct software systems and applications, allowing developers to focus on more important tasks. This chapter examines several types of middleware systems and discusses middleware capabilities, middleware operation, middleware's function in cloud-based systems, and the best middleware platforms to use. Middleware systems are widely utilised and can be found in practically any software system or application. Middleware programmes provide as a link between many sorts of systems and protocols. They serve as a mechanism for various systems. To successfully exchange information, it runs on a variety of operating system

Patients’ Perspective of Acute Post-operative Pain Management: A Multicentre Survey of Tertiary Hospitals in Maharashtra, India | Chapter 08 | New Horizons in Medicine and Medical Research Vol. 8

 When postoperative pain is adequately controlled, patients' satisfaction and patient-related outcomes (PROs) increase. Understanding the patients' perspective is crucial since it supports in the formulation of improvement strategies. Because wrong attitudes and assumptions might block pain alleviation, patients' attitudes and beliefs are critical. As a result, a multicenter study of patients' attitudes, beliefs, experiences, and satisfaction levels with acute postoperative pain management was done in Maharashtra's tertiary hospitals. In addition, the responses were examined to evaluate if the Acute Pain Service (APS) resulted in improved patient outcomes and satisfaction. A 13-item questionnaire adapted from previous studies was used to capture patients' experiences with postoperative pain treatment. The responses of 179 patients are included in the study. The findings revealed that 91.6 percent of patients experienced postoperative pain, with 75.5 percent